|Type||5 mins||15 mins||Hourly||Daily||Monthly|
|Moving Averages||Strong Sell||Strong Sell||Strong Sell||Sell||Strong Buy|
|Technical Indicators||Strong Sell||Strong Sell||BUY||Strong Sell||Strong Buy|
|Summary||Strong Sell||Strong Sell||Neutral||Strong Sell||Strong Buy|
Filter Table By:
|Pattern||Timeframe||Reliability||Candles Ago||Candle Time|
|Three Inside Up||5H||2||Nov 22, 2017 07:00AM|
|Bullish doji Star||30||2||Nov 24, 2017 12:00PM|
|Bullish doji Star||1W||3||Oct 29, 2017|
Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. The Company's marketed medicines are ORKAMBI and KALYDECO. ORKAMBI (lumacaftor in combination with ivacaftor) is approved as a treatment for patients having two copies (homozygous) of the Delta-F508 (F508del) mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene. KALYDECO (ivacaftor) is approved for the treatment of CF patients having the G551D mutation or other specified mutations in their CFTR gene. The Company's development programs in the field of CF include Tezacaftor (VX-661), VX-152, VX-440, VX-659, VX-445 and VX-371. VX-152, VX-440, VX-659 and VX-445 are CFTR corrector compounds.Read More
|National Futures Association (United States), National Securities Depository (India), U.S. Commodity Futures Trading Commission (United States), The Financial Conduct Authority (United Kingdom), Financial Industry Regulatory Authority (United States), Investment Industry Regulatory Organization of Canada (Canada), Securities and Exchange Board of India (India), Securities and Exchange Commission (United States), The Securities and Futures Commission (Hong Kong), Securities Investor Protection Corporation (United States)||$10000||Start Trading|
|U.S. Commodity Futures Trading Commission (United States)||$250||Start Trading|
|U.S. Commodity Futures Trading Commission (United States)||Start Trading|
Add a Comment
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.